BNTX — BioNTech SE

—
Nasdaq · Health Care · Biotechnology · CIK 1776985 ·
Last close
$84.86
Market Cap
$21.32B
52W High
$124.00
52W Low
$79.52
ADV30
1,085,470
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,289,200,000 1,185,900,000 138,100,000 184,500,000 20,173,800,000 10,200,800,000 2,462,100,000
Jun 2026 105,600,000 8,600,000 -938,700,000 -820,800,000 20,342,600,000 9,741,000,000 2,585,100,000
Mar 2026 118,100,000 46,700,000 -671,200,000 -531,900,000 21,074,100,000 9,939,400,000 2,376,300,000
Dec 2025 907,400,000 574,100,000 -280,500,000 -305,000,000 21,988,600,000 7,675,400,000 2,764,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-230,800,000
Investing CF
$632,600,000
Financing CF
$-329,000,000
CapEx
$-244,900,000
Dividends Paid
—
Buybacks
$-403,500,000
EPS Diluted TTM
$-5.86
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$16,793,700,000
Inventory
$64,900,000
Receivables
$796,000,000
ST Investments
$4,456,300,000
EBIT TTM
$-1,863,000,000
Pretax Income TTM
$-1,432,200,000
Interest Exp TTM
$21,900,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,649,999,872
EBITDA
$-1,380,800,000
Free Cash Flow
$-249,562,496
Enterprise Value
$11,151,198,208
Total Cash
$13,463,900,160
Total Debt
$316,100,000
Shares Out
251,204,366
Trailing EPS
$-7.81
Book Value
$82.23
ROE
-9.3%
ROA
-5.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,869,900,000 -640,700,000 -1,136,100,000 21,988,600,000 2,764,400,000 19,224,200,000 456,000,000
Dec 2024 2,751,100,000 -709,400,000 -665,300,000 22,529,700,000 3,118,600,000 19,411,100,000 207,700,000
Dec 2023 3,819,000,000 875,600,000 930,300,000 23,006,300,000 2,760,400,000 20,245,900,000 5,371,400,000
Dec 2022 17,310,600,000 12,303,800,000 9,434,400,000 23,279,100,000 3,223,500,000 20,055,600,000 13,577,400,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.69

Max Pain — expiry 2026-12-18

max pain strike: $110.00 · spot: $83.26 · call oi: 1,137 · put oi: 1,704
Expected Move to 2026-12-18: ±$7.90 (9.49%) — implied range $75.36 – $91.16 · ATM straddle on $82.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NBIX NEUROCRINE BIOSCIENCES INC $16.79B $165.92 —
EXEL EXELIXIS, INC. $16.71B $68.50 —
RVMD Revolution Medicines, Inc. $35.19B $162.69 —
BIIB BIOGEN INC. $37.07B $250.79 —
TECH BIO-TECHNE Corp $11.41B $72.63 —

News headlines (Yahoo Finance, 1h cache)

BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
2026-11-13 16:17 · Yahoo
BioNTech (BNTX) Stock Looks Fully Valued As Sales Face Pressure
2026-11-13 12:11 · Yahoo
Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
2026-11-13 10:14 · Yahoo
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
2026-11-13 09:11 · Yahoo
Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
2026-11-12 21:29 · Yahoo
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
2026-11-12 16:53 · Yahoo
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
2026-11-06 16:05 · Yahoo
BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo
2026-11-04 03:18 · Yahoo
BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...
2026-11-04 03:04 · Yahoo
Pfizer CEO Says Covid Is ‘Irrelevant.’ He’s Betting on Cancer and Weight-Loss Drugs.
2026-11-03 22:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.